Xenon Pharmaceuticals Ownership | Who Owns Xenon Pharmaceuticals?

Overview ForecastFinancials Chart Transcripts

Xenon Pharmaceuticals Ownership Summary

Xenon Pharmaceuticals is owned by 115.97% institutional investors, 0.11% insiders. Fmr is the largest institutional shareholder, holding 11.05% of XENE shares. Vanguard Health Care Inv is the top mutual fund, with 3.33% of its assets in Xenon Pharmaceuticals shares.

XENE Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Xenon Pharmaceuticals	115.97%	0.11%	-16.08%
Sector	Healthcare Stocks	246.48%	12.12%	-158.60%
Industry	Biotech Stocks	384.82%	11.76%	-296.58%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Fmr	9.65M	11.05%	$582.35M
Blackrock funding, inc. /de	7.52M	8.61%	$454.06M
Avoro capital advisors	5.78M	6.61%	$348.75M
Janus henderson group	4.18M	5.27%	$242.86M
Polar capital	4.57M	5.23%	$275.88M
Driehaus capital management	4.42M	5.06%	$266.70M
Price t rowe associates inc /md/	3.25M	3.72%	$196.06M
Jpmorgan chase	2.62M	3.00%	$157.38M
Capital investors	2.36M	2.70%	$142.55M
Blackrock	2.10M	2.70%	$81.72M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Tls advisors	30.96K	5.49%	$1.87M
Saturn v capital management	503.70K	4.44%	$20.22M
Affinity asset advisors	1.59M	4.35%	$96.27M
First turn management	600.20K	3.88%	$36.23M
Tri locum partners lp	366.10K	3.38%	$14.70M
Foresite capital management iv	160.00K	3.33%	$9.66M
Great point partners	200.00K	3.31%	$8.03M
Altium capital management lp	288.00K	3.20%	$11.29M
Avoro capital advisors	5.78M	3.13%	$348.75M
Dafna capital management	250.77K	2.89%	$15.14M

Top Buyers

Holder	Shares	% Assets	Change
Price t rowe associates inc /md/	3.25M	0.02%	1.92M
Blackrock funding, inc. /de	7.52M	0.01%	1.88M
T. rowe price investment management	2.17M	0.09%	1.22M
Two sigma investments, lp	1.64M	0.07%	1.04M
Invesco	903.46K	0.00%	844.36K

Top Sellers

Holder	Shares	% Assets	Change
Wellington management group llp	1.43M	0.01%	-3.40M
Paradigm biocapital advisors lp	-	-	-2.04M
Holocene advisors, lp	-	-	-1.52M
Citadel advisors	1.40M	0.01%	-1.25M
Fmr	9.65M	0.03%	-1.17M

New Positions

Holder	Shares	% Assets	Change	Value
Panagora asset management	664.03K	0.12%	664.03K	$40.08M
Tri locum partners lp	366.10K	3.38%	366.10K	$14.70M
Sixth street partners management company	249.47K	0.00%	249.47K	$15.06M
Axa investment managers	176.16K	0.02%	176.16K	$7.07M
Point72 asset management	130.38K	0.01%	130.38K	$7.87M

Sold Out

Holder	Change
Dinuzzo private wealth	-2.00
Tortoise investment management	-2.00
Td private client wealth	-3.00
American national bank	-5.00
Hexagon capital partners	-6.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Jun 30, 2026	323	5.56%	101,294,179	1.07%	115	0.73%	180	-12.20%	86	36.51%
Mar 31, 2026	110	-57.85%	10,120,863	-88.02%	12	0.11%	74	-45.59%	20	-73.33%
Dec 31, 2025	150	-34.78%	31,012,004	-63.22%	39	0.34%	73	-31.13%	49	-30.00%
Sep 30, 2025	142	-30.39%	50,518,761	-37.12%	63	0.61%	62	-45.13%	48	-12.73%
Jun 30, 2025	211	0.48%	83,114,839	11.81%	105	1.18%	116	26.09%	57	-18.57%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Vanguard Health Care Inv	3.21M	3.33%	-127.83K
American Funds SMALLCAP World A	2.81M	2.91%	-309.67K
Polar Capital Biotech S Inc	2.72M	2.81%	-
Strategic Advisers Fidelity US TtlStk	2.72M	2.81%	748.72K
iShares Russell 2000 ETF	2.54M	2.62%	-29.25K
Polar Capital Healthcare Opports Inc	1.69M	1.75%	-
Fidelity Small Cap Index	1.07M	1.11%	8.70K
JPM US Mid Cap Growth-Composite	962.10K	1.00%	536.10K
T. Rowe Price New Horizons	961.23K	0.99%	31.04K
T. Rowe Price Mid-Cap Growth	956.96K	0.99%	956.96K

Recent Insider Transactions

Date	Name	Role	Activity	Value
Sep 30, 2026	Kelly Thomas Patrick	Chief Financial Officer	Buy	$559.74K
Sep 30, 2026	MORTIMER IAN	PRESIDENT & CEO	Buy	$1.12M
Aug 28, 2026	KENNEY CHRISTOPHER JOHN	Chief Medical Officer	Sell	$383.15K
Aug 28, 2026	KENNEY CHRISTOPHER JOHN	Chief Medical Officer	Sell	$42.68K
Aug 11, 2026	GANNON STEVEN	-	Sell	$640.55K

Insider Transactions Trends

Date	Buy	Sell
2026 Q4	-	-
2026 Q3	2	3
2026 Q2	-	2
2026 Q1	-	17
2025 Q4	-	5

XENE Ownership FAQ

Who Owns Xenon Pharmaceuticals?

Xenon Pharmaceuticals shareholders are primarily institutional investors at 115.97%, followed by 0.11% insiders and -16.08% retail investors. The average institutional ownership in Xenon Pharmaceuticals's industry, Biotech Stocks , is 384.82%, which Xenon Pharmaceuticals falls below.

Who owns the most shares of Xenon Pharmaceuticals?

Xenon Pharmaceuticals’s largest shareholders are Fmr (9.65M shares, 11.05%), Blackrock funding, inc. /de (7.52M shares, 8.61%), and Avoro capital advisors (5.78M shares, 6.61%). Together, they hold 26.27% of Xenon Pharmaceuticals’s total shares outstanding.

Does Blackrock own Xenon Pharmaceuticals?

Yes, BlackRock owns 2.70% of Xenon Pharmaceuticals, totaling 2.1M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 81.72M$. In the last quarter, BlackRock decreased its holdings by -26.034K shares, a -1.23% change.

Who is Xenon Pharmaceuticals’s biggest shareholder by percentage of total assets invested?

Tls advisors is Xenon Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 5.49% of its assets in 30.96K Xenon Pharmaceuticals shares, valued at 1.87M$.

Who is the top mutual fund holder of Xenon Pharmaceuticals shares?

Vanguard Health Care Inv is the top mutual fund holder of Xenon Pharmaceuticals shares, with 3.33% of its total shares outstanding invested in 3.21M Xenon Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools